Your browser doesn't support javascript.
loading
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC.
Zhou, Xu; An, Jingyu; Kurilov, Roma; Brors, Benedikt; Hu, Kai; Peccerella, Teresa; Roessler, Stephanie; Pfütze, Katrin; Schulz, Angela; Wolf, Stephan; Hohmann, Nicolas; Theile, Dirk; Sauter, Max; Burhenne, Jürgen; Ei, Shigenori; Heger, Ulrike; Strobel, Oliver; Barry, Simon T; Springfeld, Christoph; Tjaden, Christine; Bergmann, Frank; Büchler, Markus; Hackert, Thilo; Fortunato, Franco; Neoptolemos, John P; Bailey, Peter.
  • Zhou X; Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.
  • An J; Section Surgical Research, University Clinic Heidelberg, Heidelberg, Germany.
  • Kurilov R; Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.
  • Brors B; Section Surgical Research, University Clinic Heidelberg, Heidelberg, Germany.
  • Hu K; Division of Applied Bioinformatics, The German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Peccerella T; Division of Applied Bioinformatics, The German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Roessler S; German Cancer Consortium (DKTK), Core Center Heidelberg, Heidelberg, Germany.
  • Pfütze K; National Center for Tumour Disease (NCT), Heidelberg, Germany.
  • Schulz A; Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.
  • Wolf S; Section Surgical Research, University Clinic Heidelberg, Heidelberg, Germany.
  • Hohmann N; Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.
  • Theile D; Section Surgical Research, University Clinic Heidelberg, Heidelberg, Germany.
  • Sauter M; Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
  • Burhenne J; Department of Translational Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, The German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Ei S; NGS Core Facility, The German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Heger U; NGS Core Facility, The German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Strobel O; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
  • Barry ST; Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany.
  • Springfeld C; Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany.
  • Tjaden C; Department of Clinical Pharmacology and Pharmacoepidemiology, Heidelberg University Hospital, Heidelberg, Germany.
  • Bergmann F; Department of Gastroenterological Surgery, Tokai University School of Medicine, Kanagawa, Japan.
  • Büchler M; Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.
  • Hackert T; Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.
  • Fortunato F; Department of General Surgery, Division of Visceral Surgery, Medical University of Vienna, Vienna, Austria.
  • Neoptolemos JP; Bioscience, Early Oncology, AstraZeneca, Cambridge, UK.
  • Bailey P; Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany.
Nat Cancer ; 4(9): 1362-1381, 2023 09.
Article en En | MEDLINE | ID: mdl-37679568

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Adenocarcinoma / Terapia Neoadyuvante Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Adenocarcinoma / Terapia Neoadyuvante Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article